Advertisement

Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease

Juan-José Lahuerta, Ana Jiménez-Ubieto, Bruno Paiva, Joaquín Martínez-López, José González-Medina, Lucía López-Anglada, María-Teresa Cedena, Noemi Puig, Albert Oriol, María-Jesús Blanchard, Rafael Ríos, Jesús Martin, Rafael Martínez, Anna Sureda, Miguel Teodoro Hernández, Javier de la Rubia, Isabel Krsnik, Valentín Cabañas, Luis Palomera, Joan Bargay, María-Victoria Mateos, Laura Rosiñol, Jesús F. San Miguel and Joan Blade

Article Figures & Data

Figures

Tables

  • Table 1.

    Rates of MRD-negative responses and 2-year PFS rates, assessed at landmarks of postinduction, post-ASCT, and postconsolidation time points, in patients achieving CR, uCR, and VGPR

    Best response at time pointP value for comparison
    CR*uCRVGPRCR vs uCRuCR vs VGPRCR vs VGPR
    MRD assessment
     Postinduction, N evaluable1266997
     MRD-negative rate, n (%)66 (52%)40 (58%)15 (15%).4<.0001<.0001
     Post-ASCT, N evaluable12397105
     MRD-negative rate, n (%)84 (68%)76 (78%)30 (29%).1<.0001<.0001
     Postconsolidation, N evaluable10311380
     MRD-negative rate, n (%)78 (76%)85 (75%)22 (28%).9<.0001<.0001
    PFS
     From postinduction time point; median follow-up 31.1 mo, N12972106
     2-y PFS rate (95% CI)93% (88-97)88% (81-94)78% (69-86).5.001.02
     From ASCT time point, median follow-up 26.4 mo, N133105116
     2-y PFS rate (95% CI)88% (82-94)87% (81-94)77% (68-85).7.05.1
     From postconsolidation time point, median follow-up 23.5 mo, N14911885
     2-y PFS rate (95% CI)85% (80-96)88% (82-95)76% (68-85).4.1.3
    • CI, confidence interval.

    • * CR includes patients in stringent CR in the following proportions: post-induction, 64%; post-ASCT, 76%; and postconsolidation, 79%.